Novartis Sends “Dear Doctor” Letter On Clozaril
This article was originally published in The Pink Sheet Daily
Executive Summary
Clarification of white blood cell monitoring schedule is key concern of the letter.
You may also be interested in...
Clozapine Reaction Shows Comparative Effectiveness In Transition
A recent study in The Lancet generated significant attention after showing much lower death rates for schizophrenia sufferers taking the cheap generic antipsychotic clozapine compared with branded drugs
Clozapine Reaction Shows Comparative Effectiveness In Transition
A recent study in The Lancet generated significant attention after showing much lower death rates for schizophrenia sufferers taking the cheap generic antipsychotic clozapine compared with branded drugs
Novartis Clozaril Blood Monitoring Requirements Relaxed By FDA
FDA agrees to labeling change decreasing monitoring requirements for agranulocytosis to once monthly from twice a month. The agency asks Novartis to track agranulocytosis rates in the national registry.